Tivantinib Overview April 2016

Size: px
Start display at page:

Download "Tivantinib Overview April 2016"

Transcription

1 Tivantinib Overview April 2016

2 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical trials with the Company s product candidates, including tivantinib (ARQ 197), ARQ 092, ARQ 087, ARQ 761, ARQ 751 and ARQ 531, competitive products, financial operations and results, corporate partnerships and other future business objectives, opportunities and strategies. Forward-looking statements are typically identified by words such as believe, expect, anticipate, intend, outlook, position and similar expressions, or future or conditional verbs such as will, should, would, and could. Forward-looking statements are subject to numerous assumptions, risks and uncertainties. Forward-looking statements speak only as of today, and ArQule assumes no obligation to update them. Actual results may differ materially from forward-looking statements or historical performance due to the factors discussed in this presentation and factors previously disclosed in ArQule s SEC reports. See discussion of Risk Factors in the Company s Annual Report on Form 10-K as filed with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. ArQule s product candidates are in various stages of development and are not available for sale or use outside of approved clinical trials. ArQule and the ArQule logo are registered trademarks of ArQule, Inc. 2

3 Pipeline of Products Tivantinib C-MET ARQ 087 FGFR ARQ 092 AKT ARQ 751 AKT ARQ 761 NQO1 ARQ 531 BTK Pre-Clinical Phase 1a/1b Phase 2 Phase 3 Collaborator METIV-HCC Trial (West) Fully Enrolled JET-HCC Trial (Japan) Intrahepatic Cholangiocarcinoma (icca) Solid Tumors Solid tumors/endometrial/ lymphoma cancer - Fully Enrolled Proteus syndrome Other Rare Diseases Cancer/ Rare Diseases Solid Tumors/Pancreatic Cancer Cancer Regulatory Designation SPA Orphan Drug Designation Orphan Drug Designation Orphan Drug Designation 3

4 Tivantinib in HCC Snapshot Tivantinib is a class leading investigational oral inhibitor of the MET receptor tyrosine kinase currently in phase 3 clinical development in two biomarkerdefined trials for second-line treatment of hepatocellular carcinoma (HCC) in a MET-high population METIV-HCC trial being conducted in the West (U.S., Europe, South America, and rest of world), partnered with and co-funded with Daiichi Sankyo¹; this trial is fully accrued JET-HCC trial being conducted in Asia (Japan and select Asian countries), partnered with and funded by Kyowa Hakko² Previous studies support drug activity in MET-high patients In NSCLC (non-small cell lung cancer) a pre-defined sub-analysis from phase 3 trial, MARQUEE In HCC (hepatocellular carcinoma) a successful randomized double blind phase 2 trial In CRC (colorectal cancer) Stage 1 data from a phase 2 investigator-initiated trial In HCC, phase 3 METIV-HCC trial preliminary analysis of baseline MET status Granted Orphan Drug Status for HCC by the FDA and EMA Composition of Matter patent protection through 2030 (U.S.) ¹ Development and Commercialization partnership with Daiichi Sankyo for U.S., Europe, South America, and rest of world. ² Development and Commercialization partnership with Kyowa Hakko for Japan, and select Asian countries. 4

5 Tivantinib Milestones in HCC Phase 1 EXPLORATORY December 2008 Trial initiated January 2010 Preliminary trial results presented at ASCO GI October 2010 Final trial results presented at ESMO Phase 2 PROOF OF CONCEPT September 2010 January 2012 June 2012 January 2013 Trial initiated Trial meet primary endpoints Trial results presented at ASCO Trial results published in Lancet Phase 3 REGISTRATION January 2013 METIV-HCC (second-line HCC) initiated September 2013 Dosage change implemented November 2015 Exercised co-commercialization option in U.S. with Daiichi Sankyo December 2015 Completed accrual March 2016 Completed planned interim analysis trial to continue 5

6 Liver Cancer Facts 782,000 cases diagnosed annually 6 th most common cancer worldwide Liver Cancer A Worldwide Disease 746,000 deaths annually 2 nd most common cause of cancer related death About 90% of all liver cancers are HCC Most cases diagnosed >75 years old Risks include age, cirrhosis, hepatitis A and B and smoking Five Year Survival Rate is 12% Early stages generally do not show symptoms Source: World Cancer Research Fund International/American Institute for Cancer Research. Continuous Update Project Report: Diet, Nutrition, Physical Activity and Liver Cancer Available at: wcrf.org/sites/default/files/liver-cancer-2015-report.pdf 6

7 About Liver Cancer Liver cancer is the abnormal and uncontrolled growth of cells within the liver that disrupt normal liver function. It is typically defined as either primary liver cancer, which starts in the liver, or secondary liver cancer, and spreads to the liver from another part of the body such as the pancreas, colon, stomach, breast or lung. There are four types of primary liver cancer: 1. Hepatocellular carcinoma (HCC): The most common type of liver cancer, HCC starts in the hepatocyte cells of the liver and can have different growth patterns. It can start as a single tumor that grows larger, and only late in the disease does it spread to other parts of the liver. Other times, it can start as many small cancer nodules throughout the liver, which is usually seen in people with cirrhosis. 2. Intrahepatic cholangiocarcinoma (icca): This type of liver cancer (bile duct cancer) starts in the bile ducts (the tubes that carry bile to the gallbladder) within the liver. 3. Angiosarcoma and hemagiosarcoma: These are rare types that start in the blood vessels of the liver. 4. Hepatoblastoma: A very rare type of cancer that develops in children under four years of age. 7

8 HCC High Unmet Need Limited Treatment Options for HCC Current treatment options¹ Surgery Tumor ablation Embolization therapy Radiation treatment Targeted therapy 1 st line therapy - sorafenib is the only approved systemic agent Need for 2 nd line therapy No standard of care exists at this time for 2 nd line therapy Several phase 3 studies in 2 nd line HCC failed brivanib, everolimus, and ramucirumab Tivantinib is the only drug in a biomarker-driven phase 3 trial for HCC ¹ American Cancer Society. Liver Cancer Overview. 8

9 The Role of MET in HCC Amplification and overexpression of the MET pathway is associated with poor outcomes in many cancers, including HCC In cancer cells, MET is dysregulated continuously thus playing a role in cancer cell growth, survival, angiogenesis, invasion and metastasis HGF/MET signaling plays a role in liver regeneration [1] and MET expression is reported to be increased in some HCC tumors [2-4] MET overexpression by IHC correlates with poor prognostic features and poor outcomes [6-8] HGF overexpression and subsequent autocrine MET activation can induce tumor growth in transgenic in vivo models [5] Elevated plasma HGF associated with decreased benefit from sorafenib in SHARP study [9] 1. Borowiak M, et al. Proc Natl Acad Sci U S A. 2004;101: Kiss A, et al. Clin Cancer Res. 1997;3: Selden C, et al. J Hepatol. 1994;21: Tavian D, et al. Int J Cancer. 2000;87: Horiguchi N, et al. Oncogene. 2002;21: Ueki T, et al. Hepatology. 1997;25: Wu FS, et al. Chin J Surg. 2006;44: Santoro A, et al. Lancet Oncol. 2013;14: Llovet JM, et al. Clin Cancer Res. 2012;18:

10 Phase 2 HCC MET Data Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Volume 14, Issue 1, Pages 55-63, January 2013 MET-high Patients Placebo controlled, double blind in patients with advanced HCC and Child-Pugh cirrhosis who progressed or were unable to tolerate first-line systemic therapy 2:1 randomization to receive tivantinib or placebo until disease progression; 37 MET-high patients In the MET-high sub group, median time to progression (TTP) was 2.7 months (95% CI ) in the tivantinib group compared with 1.4 months (95% CI ) in the placebo group (HR 0.43, 95% CI ; p=0.03) Median overall survival was 7.2 months (95% CI ) for patients with MET-high tumours who received tivantinib versus 3.8 months (95% CI ) for patients who received placebo (HR 0.38, 95% CI ; p=0.01) 10

11 Tumor H-Score Tumor H-Score METIV-HCC vs. Phase 2 Baseline Phase 2 HCC Baseline Tumor MET Status 1 Phase 3 METIV-HCC Preliminary Baseline Tumor MET Status* 1 H-Score Median Min Max MET-High Patients MET-Low Patients * Data are preliminary, from non-cleaned database, from biopsied patients regardless of enrollment status ¹ Rimassa, L. et al Gastrointestinal Cancers Symposium. Abstr #197. H-Score Median Min Max MET-High Patients MET-Low Patients Similar patient tumor MET-high population for phase 2 trial and phase 3 METIV-HCC trial 11

12 MET Status After Sorafenib Phase 2 HCC Baseline Tumor MET Status 1 MET-High Samples (rate) Tested samples (N=77) 37 (48%) Phase 3 METIV-HCC Preliminary Baseline tumor MET Status* 1 MET-High Samples (rate) Tested samples (N=1138) 576 (51%) Samples with available biopsy data (N=72) 36 (50%) Samples with available biopsy date (N=925) 527 (57%) Tumor samples taken before sorafenib (N=55) 22 (40%) Tumor samples taken before sorafenib (N=438) 173 (39%) Tumor samples taken after sorafenib (N=17) 14 (82%) Tumor samples taken after sorafenib (N=487) 354 (73%) In both the phase 2 trial and the phase 3 METIV-HCC trials the rate of tumor MET-high patients was higher after sorafenib treatment * Data are preliminary, from non-cleaned database, from biopsied patients regardless of enrollment status ¹ Rimassa, L. et al Gastrointestinal Cancers Symposium. Abstr #

13 Phase 3 MARQUEE MET Data MET-High NSCLC Phase 3 trial of 1,048 patients, selected by non-squamous cell histology previously receiving one to two systemic treatments, tivantinib in combination with erlotinib versus erlotinib plus placebo Trial was discontinued for futility at planned interim analysis in Q In the intent to treat (ITT) population overall survival (8.5 vs 7.8 months, HR = 0.98, 95% CI = 0.84;1.15) improved but was not significant while improvement in progression free survival (3.6 vs 1.9 months, HR = 0.74, CI 0.64;0.85) demonstrated significance Approximately 500 patients were able to be analyzed for MET status per protocol; of these, 211 patients where confirmed as being MET-high of which 104 and 107 patients, respectively, where enrolled in the tivantinib and the placebo arms of the trial¹. A pre-specified exploratory analysis indicated improved median overall survival (9.3 vs 5.9 months, HR = 0.70, 95% CI = 0.49;1.01) and progression-free survival (3.7 vs 1.9 months, HR = 0.72, 95% CI = 0.52;0.98) in patients with high MET expression¹ ¹ Scagliotti, G. et al. ESMO

14 Phase 2 CRC MET Data Progression Free Survival Months Overall Survival Months Investigator-initiated (two stage) Phase 2 single-arm study evaluating tivantinib in combination with cextuximab in EGFR-inhibitor resistant, MET-high, KRAS wild-type colorectal cancer patients failing at least one systemic therapy 21 patients enrolled in Stage 1 with the primary end point of overall survival Stage 1 results 1 patient experienced a complete response (CR) 2 patients experienced durable confirmed partial responses (PRs) Stable disease was observed in 8 patients, including 2 short duration PRs, for an overall Disease Control Rate of (CR + PR + SD) 52.4% The trial has continued to Stage 2 and is expected to be completed by year-end 2015 ¹ Rimassa, L. et al. ESMO 17 th Annual World Congress on Gastrointestinal Cancer Abstr #O-DD8. 14

15 Tivantinib Phase 3 Trial Design METIV-HCC (West)¹ (NCT ) MET-high patients receiving tivantinib in advanced HCC Patients with MET-high (assessed by IHC) inoperable locally advanced metastatic HCC treated with 1 prior systemic therapy (sorafenib) Companion diagnostic Conducted under FDA SPA Stratification Factors Vascular invasion Extra-hepatic spread AFP (< or > 200 ng/ml) Endpoints 1 o : OS Tivantinib 120 mg tablet BID* 2 : PFS, safety ~200 pts Placebo ~100 pts 3 : ORR, DCR, TTP, PD, PK, biomarkers *Dose reduced from 240 mg tablet twice daily (BID) to 120 mg tablet BID following observation of higher incidence of neutropenia. DMC safety analysis of reduced dose cleared the trial to proceed. PK analysis of DMC-determined cohort demonstrated that 120 mg tablet BID has comparable exposure to 240 mg capsule as per the Phase 2 trial data. R A N D O M I Z E D ¹ Development and Commercialization partnership with Daiichi Sankyo for U.S., Europe, South America, and rest of world. 15

16 Tivantinib Financials Daiichi Sankyo Partnership¹ Costs of development are shared 50/50; however, Daiichi is responsible for all phase 3 costs and ArQule reimburses only if milestones and royalties are realized ArQule has received a total of $100 million in upfront and milestone payments from Daiichi and currently owes $59 million for its share of the phase 3 trial Potential for up to an additional approximated $500 million in development and sales milestones Upon commercialization, ArQule will receive tiered, double-digit royalties, starting at 20%, on net sales of tivantinib and has a co-commercialization option in the U.S. Daiichi pays all costs of commercialization, including costs of an ArQule salesforce Kyowa Hakko Kirin Partnership² All development and commercial costs are borne by KHK ArQule has received a total of $48 million in upfront and milestone payments from KHK Potential for up to an additional $75 million in regulatory milestones plus undisclosed sales milestones Upon commercialization, ArQule will receive tiered royalties in the mid-teen to low-twenty percent range on net sales of tivantinib ¹ Development and Commercialization partnership with Daiichi Sankyo for U.S., Europe, South America, and rest of world. ² Development and Commercialization partnership with Kyowa Hakko for Japan, and select Asian countries. 16

17 METIV-HCC Interim Analysis Trial Design Primary Endpoint Overall Survival (OS) > 257 events required Median OS assumptions 7.7 months in treatment arm 5.0 months in placebo arm Hazard ratio = 0.65 Interim Analysis Triggered with ~ 154 OS events DMC was to review and determine: Efficacy stop Continue trial No planned futility stop Minimal alpha spend Analysis occurred March 2016 Trial to run to completion Expect METIV-HCC trial to complete by year-end

ArQule Jefferies Global Healthcare Conference June 2015

ArQule Jefferies Global Healthcare Conference June 2015 ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning

More information

July, ArQule, Inc.

July, ArQule, Inc. July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical

More information

Corporate Overview. April 2016

Corporate Overview. April 2016 Corporate Overview April 2016 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with

More information

ARQ 087 Overview. FGFR Inhibitor. March 2017

ARQ 087 Overview. FGFR Inhibitor. March 2017 ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform

More information

ArQule CorporateUpdate

ArQule CorporateUpdate ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform

More information

Jefferies 2014 Global Healthcare Conference. June 5, 2014

Jefferies 2014 Global Healthcare Conference. June 5, 2014 Jefferies 2014 Global Healthcare Conference June 5, 2014 ArQule, Inc. Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private

More information

Investor Presentation February 2016

Investor Presentation February 2016 Investor Presentation February 2016 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act

More information

12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval

12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval 12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization

More information

Riunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs

Riunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology

More information

Randomized Controlled Phase 2 Trial (RCT) ARQ

Randomized Controlled Phase 2 Trial (RCT) ARQ Tivantinib in Pretreated Hepatocellular Carcinoma (HCC): Tumor and Plasma Biomarker Analysis from the Randomized Controlled Phase 2 Trial (RCT) ARQ 197-215 L Rimassa, G Abbadessa, N Personeni, C Porta,

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical

More information

The Current Champion: Angiogenesis inhibitors

The Current Champion: Angiogenesis inhibitors The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation

More information

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show

More information

Stifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014

Stifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014 Stifel Healthcare Conference 2014 John Scarlett, M.D. Chief Executive Officer November 19, 2014 1 forward-looking statements Except for statements of historical fact, the statements during this presentation

More information

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University 2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling

More information

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14): Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,

More information

Jefferies 2015 Global Healthcare Conference. June 2015 CORP OVERVIEW

Jefferies 2015 Global Healthcare Conference. June 2015 CORP OVERVIEW Jefferies 2015 Global Healthcare Conference June 2015 CORP OVERVIEW Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)

More information

Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell

Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell carcinoma patients June 2013 Carbonic Anhydrase IX (CAIX):

More information

Oncology Therapeutics without Compromise APRIL 2011

Oncology Therapeutics without Compromise APRIL 2011 Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other

More information

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year

More information

New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain

New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain PHC 2018 - www.aphc.info EASL-EORTC Guidelines EASL EORTC Guidelines. J Hepatol. 2012;56:908-43. Systemic

More information

Spectrum Pharmaceuticals

Spectrum Pharmaceuticals Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future

More information

Second Line Therapy in Hepatocellular Carcinoma (HCC): A Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197)

Second Line Therapy in Hepatocellular Carcinoma (HCC): A Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197) Second Line Therapy in Hepatocellular Carcinoma (HCC): A Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197) C Porta, I Borbath, L Rimassa, B Daniele, S Salvagni, JL Van Laethem, H Van

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within

More information

Broad Spectrum, Targeted Approaches To Cancer Treatment

Broad Spectrum, Targeted Approaches To Cancer Treatment SELECTIVELY KILLING CANCER CELLS Broad Spectrum, Targeted Approaches To Cancer Treatment Safe Harbor The presentation made during this meeting and other statements by ArQule may contain forward-looking

More information

MOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014

MOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014 Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,

More information

33 rd Annual J.P. Morgan Healthcare Conference. January 2015

33 rd Annual J.P. Morgan Healthcare Conference. January 2015 33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.

More information

Under the terms of the agreement, AVEO will receive an initial cash payment of $125 million, composed of a $75 million license fee and $50 million in

Under the terms of the agreement, AVEO will receive an initial cash payment of $125 million, composed of a $75 million license fee and $50 million in Astellas Pharma Inc. AVEO Pharmaceuticals Corporate Communications Investor Contact: Astellas Pharma Inc. Monique Allaire AVEO Pharmaceuticals +81(3)-3244-3201 (617) 299-5810 Media Contact: Dan Budwick

More information

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated

More information

DS-8201 Strategic Collaboration

DS-8201 Strategic Collaboration DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections

More information

Developing & Commercializing Targeted Small Molecule Drugs in Cancer

Developing & Commercializing Targeted Small Molecule Drugs in Cancer Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions

More information

Liver and Biliary Tract Cancers Critical Review

Liver and Biliary Tract Cancers Critical Review Liver and Biliary Tract Cancers Critical Review Lorenza Rimassa Oncologia Medica e Ematologia Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Critical review Oral presentations Melero

More information

Dicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies

Dicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including

More information

Ipsen announces CELESTIAL phase 3 pivotal trial results in the New England Journal of Medicine

Ipsen announces CELESTIAL phase 3 pivotal trial results in the New England Journal of Medicine PRESS RELEASE Ipsen announces CELESTIAL phase 3 pivotal trial results in the New England Journal of Medicine Trial results formed the basis of regulatory filings in the U.S. and European Union for CABOMETYX

More information

March Corporate Presentation

March Corporate Presentation March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements

More information

Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018

Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"

More information

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016 ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),

More information

Delcath Investor Presentation (OTCQB: DCTH)

Delcath Investor Presentation (OTCQB: DCTH) Delcath Investor Presentation (OTCQB: DCTH) December 2018 1 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities

More information

AVEO and Astellas Report Final Overall Survival Results from TIVO-1

AVEO and Astellas Report Final Overall Survival Results from TIVO-1 AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,

More information

K-Ras signalling in NSCLC

K-Ras signalling in NSCLC Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer

More information

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation

More information

National Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.

National Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved. National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.

More information

MOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO

MOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO Pioneering Immune Therapy Q1 Results 2014 Conference Call Dr. Matthias Schroff, CEO Berlin, 14 May 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to

More information

Revolutionizing the Treatment of Cancer

Revolutionizing the Treatment of Cancer Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may

More information

MOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013

MOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013 Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,

More information

蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 )

蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 1 Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase III Randomized, -Controlled Trial Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip

More information

Advances in Systemic Therapy Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016

Advances in Systemic Therapy Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016 Advances in Systemic Therapy for Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016 Scope Background Staging and treatment strategies Current systemic therapy

More information

Flexibility, Resilience, Understanding the Science: Phase 1 and Beyond?

Flexibility, Resilience, Understanding the Science: Phase 1 and Beyond? Clinical Operations in Oncology Trials Boston, July 15 th 2015 Flexibility, Resilience, Understanding the Science: Phase 1 and Beyond? Giovanni Abbadessa, MD, PhD Vice President Clinical Development, Translational

More information

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

Drug Discovery Platform: Cancer Cell Signaling. MET Inhibitor. Merestinib, LY Christensen JG, et al1; Eder JP, et al 2

Drug Discovery Platform: Cancer Cell Signaling. MET Inhibitor. Merestinib, LY Christensen JG, et al1; Eder JP, et al 2 MET Inhibitor Drug Discovery Platform: Cancer Cell Signaling Christensen JG, et al1; Eder JP, et al 2 A Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus and Gemcitabine

More information

Il treatment plan nella terapia sistemica dell epatocarcinoma

Il treatment plan nella terapia sistemica dell epatocarcinoma Il treatment plan nella terapia sistemica dell epatocarcinoma M. Iavarone, MD PhD CRC A.M. e A. Migliavacca Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione

More information

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,

More information

Revolutionizing the Treatment of Cancer

Revolutionizing the Treatment of Cancer Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results

More information

Nexavar in advanced HCC: a paradigm shift in clinical practice

Nexavar in advanced HCC: a paradigm shift in clinical practice Nexavar in advanced HCC: a paradigm shift in clinical practice Tim Greten Hanover Medical School, Germany Histopathological progression and molecular features of HCC Chronic liver disease Liver cirrhosis

More information

Third Quarter 2015 Earnings Call. November 9, 2015

Third Quarter 2015 Earnings Call. November 9, 2015 Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements

More information

Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer

Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study

More information

Jefferies Global Healthcare Conference New York 2014

Jefferies Global Healthcare Conference New York 2014 Jefferies Global Healthcare Conference New York 2014 Disclaimer This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other

More information

MET Inhibitor. Merestinib, LY Drug Discovery Platform: Cancer Cell Signaling. Derived from Christensen JG, et al 1 ; Eder JP, et al.

MET Inhibitor. Merestinib, LY Drug Discovery Platform: Cancer Cell Signaling. Derived from Christensen JG, et al 1 ; Eder JP, et al. MET Inhibitor Merestinib, LY2801653 Derived from Christensen JG, et al 1 ; Eder JP, et al. 2 Drug Discovery Platform: Cancer Cell Signaling A Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib

More information

Revolutionizing the Treatment of Cancer

Revolutionizing the Treatment of Cancer Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may

More information

Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC

Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts

More information

Investor Call. May 19, Nasdaq: IMGN

Investor Call. May 19, Nasdaq: IMGN Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not

More information

Investor Presentation

Investor Presentation Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance

More information

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented

More information

Genta Incorporated. A Multiproduct Late-Stage Oncology Company

Genta Incorporated. A Multiproduct Late-Stage Oncology Company Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking

More information

CORPORATE PRESENTATION

CORPORATE PRESENTATION CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

More information

Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer

Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com Regorafenib from Bayer Submitted

More information

Corporate Overview May 8, 2014

Corporate Overview May 8, 2014 0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements

More information

Corporate Presentation

Corporate Presentation Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains

More information

Company presentation. Claudio Bordignon, Chairman and CEO. Jefferies Global Healthcare Conference New York, 7 June 2012

Company presentation. Claudio Bordignon, Chairman and CEO. Jefferies Global Healthcare Conference New York, 7 June 2012 Company presentation Claudio Bordignon, Chairman and CEO Jefferies Global Healthcare Conference New York, 7 June 2012 Forward-looking statements The presentation contains certain forward-looking statements.

More information

Announce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017

Announce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017 AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting Announce Expected Initiation of an Investigator-Initiated,

More information

Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma

Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca

More information

Il Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali

Il Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali Il Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali Lorenza Rimassa Medical Oncology Unit Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Disclosures

More information

Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer

Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies

More information

Combined treatment with MET inhibitors and other therapies in lung cancer

Combined treatment with MET inhibitors and other therapies in lung cancer Perspective Combined treatment with MET inhibitors and other therapies in lung cancer Rakesh Bagai 1,2, Patrick C. Ma 1,2,3 1 Translational Hematology and Oncology Research, and 2 Solid Tumor Oncology,

More information

AACR 2018 Investor Meeting

AACR 2018 Investor Meeting AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for

More information

Nintedanib in Oncology Backgrounder

Nintedanib in Oncology Backgrounder For media outside the US, UK and Canada only Nintedanib in Oncology Backgrounder 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. Additional clinical data 5. Nintedanib approval

More information

A Fully Integrated Cancer Company.

A Fully Integrated Cancer Company. A Fully Integrated Cancer Company. Jefferies Global Healthcare Conference June 3, 2014 Robert Mulroy, President and CEO Forward Looking Statements To the extent that statements contained in this presentation

More information

Dawson James Conference

Dawson James Conference Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding

More information

Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories

Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation

More information

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018 MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward

More information

35 th Annual J.P. Morgan Healthcare Conference

35 th Annual J.P. Morgan Healthcare Conference 35 th Annual J.P. Morgan Healthcare Conference Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's

More information

Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma

Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM

More information

FORWARD II PROGRAM UPDATE

FORWARD II PROGRAM UPDATE FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,

More information

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER

More information

OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER

OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER & OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina

More information

Combining HS-110 and anti-pd-1 in NSCLC. September 1, 2015

Combining HS-110 and anti-pd-1 in NSCLC. September 1, 2015 Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking

More information

Long Term Results in GIST Treatment

Long Term Results in GIST Treatment Long Term Results in GIST Treatment Dr. Laurentia Gales Prof. Dr. Rodica Anghel, Dr. Xenia Bacinschi Institute of Oncology Prof Dr Al Trestioreanu Bucharest 25 th RSRMO October 15-17 Sibiu Background Gastrointestinal

More information

Corporate Presentation March 2016

Corporate Presentation March 2016 Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

More information

Recent Advances in Gastrointestinal Cancers

Recent Advances in Gastrointestinal Cancers Recent Advances in Gastrointestinal Cancers Ursina R. Teitelbaum, MD Section of Hematology/Oncology Abramson Cancer Center PENN 2016 Updates in Oncology June 23, 2016 none Disclosures ASCO 2016 Highlights:

More information

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical

More information

Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy

Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy Oncogenic drivers in NSCLC Certain tumours arise as a result of aberrant activation

More information

Revefenacin (TD-4208) Phase 3 Efficacy Results

Revefenacin (TD-4208) Phase 3 Efficacy Results Revefenacin (TD-4208) Phase 3 Efficacy Results Once-daily, Nebulized Long-Acting Muscarinic Antagonist (LAMA) October 20, 2016 THERAVANCE, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE are registered

More information

Delcath Investor Presentation (OTCQB: DCTH)

Delcath Investor Presentation (OTCQB: DCTH) Delcath Investor Presentation (OTCQB: DCTH) March 2018 1 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities

More information

When patients fail on molecular targeted therapy: what to do in 2013

When patients fail on molecular targeted therapy: what to do in 2013 When patients fail on molecular targeted therapy: what to do in 2013 For 3 rd APASAL HCC conference on 23 Nov 2013 Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong

More information

Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018

Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains

More information

Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle

Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout

More information